Daix (France), Long Island City (New York, United States), October 21, 2021 Daix (France) – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical need, today announces the selection of a successful scientific abstract for poster presentation at The Liver Meeting™ 2022 , hosted by the American Association for the Study of Liver Diseases (AASLD) to be held November 4-8, 2022 in Washington, DC.